ASCO GU 2019: Interviews with the experts
The following interviews with kidney cancer experts were recorded by [...]
ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer
New 30-month survival data from the CheckMate 214 study were [...]
ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib
The results from the following study were presented at the [...]
ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib
The results from the following study were presented at the [...]
ASCO GU 2019: Nivolumab monotherapy for non-clear cell renal cell carcinoma
The results from the following study were presented at the [...]
ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer
The results from the following study were presented at the [...]
ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA
The following survey assessed patient views related to cytoreductive nephrectomy [...]
ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer
Results from this trial for patients with non-clear cell renal [...]
ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer
Results from this trial for papillary renal cell carcinoma (RCC) [...]
ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC
The results from the following study were presented at the [...]
